Compare CORT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | ALKS |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.7B |
| IPO Year | 2001 | 2012 |
| Metric | CORT | ALKS |
|---|---|---|
| Price | $113.79 | $44.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $96.50 | $43.43 |
| AVG Volume (30 Days) | 823.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $761,407,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $26.08 | $24.26 |
| Revenue Next Year | $26.98 | $4.47 |
| P/E Ratio | $1,224.56 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $26.99 |
| 52 Week High | $126.38 | $55.67 |
| Indicator | CORT | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 36.04 |
| Support Level | $108.25 | $36.25 |
| Resistance Level | $124.30 | $51.25 |
| Average True Range (ATR) | 5.29 | 1.44 |
| MACD | -0.76 | -0.15 |
| Stochastic Oscillator | 61.04 | 20.44 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.